Rashtriya Newsflash

Ebola Virus Therapeutics Pipeline

DelveInsight’s “Ebola Virus Competitive Landscape” report delivers extensive global insights into Ebola virus candidates across multiple stages of clinical development. Major pharmaceutical companies are strategically working to strengthen the pipeline and unlock future growth opportunities within the Ebola virus therapeutic space.

Key Highlights from the Ebola Virus Pipeline Report

• DelveInsight’s competitive intelligence analysis outlines a dynamic pipeline landscape featuring 18+ active companies collectively developing over 20 investigational Ebola virus therapies.
• Leading developers such as Auro Vaccines, INOVIO Pharmaceuticals, RedHill Biopharma Ltd., Emergent BioSolutions, Arisan Therapeutics, TFF Pharmaceuticals, China Immunotech, and others are assessing innovative therapeutic options to enhance the current treatment paradigm.
• Prominent pipeline candidates including Ebola virus vaccine, INO 4201, Opaganib, RHB-107, Pan–Ebola, ARN 75092, Viral Vaccine Research Programs, EBV TCR T cell therapy, among others—are progressing through various stages of clinical and preclinical development.

Recent Advancements in the Ebola Treatment Landscape

• In May 2024, RedHill received a Chinese Notice of Allowance for a patent covering opaganib as a therapy targeting single-stranded RNA viruses, including Ebola virus disease, with protection extending through 2035.
• In November 2023, SK Bioscience entered into a partnership with Hilleman Laboratories Singapore to develop a cost-effective, next-generation manufacturing process for a second-generation Ebola-Zaire vaccine.
• In October 2023, RedHill Biopharma announced that oral opaganib demonstrated a statistically significant survival benefit in a USAMRIID in vivo Ebola study, marking it as the first host-directed molecule to show activity in Ebola virus disease.

Request a sample copy to explore the latest advancements in Ebola virus drug development through the Ebola Virus Pipeline Report.

Ebola Virus Overview

The Ebola virus is a highly infectious and often fatal pathogen responsible for Ebola Virus Disease (EVD). Classified under the Filoviridae family, it primarily infects humans and nonhuman primates. Transmission to humans typically occurs through contact with infected animals such as fruit bats or primates, particularly through exposure to blood, secretions, or organs. Human-to-human spread occurs via direct contact with bodily fluids of infected individuals or contaminated materials.

Ebola outbreaks are most frequently reported in specific African regions, particularly near rainforest areas. Symptoms generally develop within 2 to 21 days following exposure. Initial manifestations include fever, muscle aches, severe headaches, and fatigue, which may progress to vomiting, diarrhea, rash, liver and kidney dysfunction, and in severe cases, internal and external bleeding.

Diagnosis relies on clinical assessment supported by laboratory testing methods such as RT-PCR, ELISA, and antigen detection assays. Early detection plays a critical role in outbreak containment. While no definitive cure exists, supportive medical care—including fluid replacement, oxygen therapy, blood pressure stabilization, and management of secondary infections—can substantially improve survival outcomes. Investigational therapies such as monoclonal antibodies and antiviral agents have demonstrated encouraging results. Vaccines like rVSV-ZEBOV, deployed during the 2014–2016 outbreak, have significantly contributed to outbreak control efforts.

Ebola Virus Pipeline Analysis: Featured Drug Profile

Inmazeb: Regeneron Pharmaceuticals

Inmazeb (formerly REGN-EB3) was developed using Regeneron’s VelocImmune platform along with its VelociSuite technologies. The therapy comprises three monoclonal antibodies—atoltivimab, maftivimab, and odesivimab each targeting distinct, non-overlapping regions of the Zaire ebolavirus glycoprotein. Together, these antibodies neutralize the virus by blocking cellular entry and facilitating immune-mediated destruction of infected cells.

The therapy is administered as a single intravenous infusion dosed according to body weight (50 mg/kg each of the three antibodies). Development support was provided by BARDA under contracts with the US Department of Health and Human Services.

Learn more about Ebola virus therapeutic developments in the Ebola Virus Analysis @ https://www.delveinsight.com/sample-request/ebola-virus-competitive-landscape

Ebola Virus Market Dynamics

The market landscape for Ebola therapeutics has evolved considerably in response to recurring outbreaks and heightened global preparedness efforts. Given the virus’s high fatality rate and concentration in West and Central Africa, significant attention has been directed toward strengthening vaccines, therapeutics, diagnostics, and containment strategies. These efforts have driven investments in R&D, manufacturing capabilities, and healthcare infrastructure, supported by governments, global health agencies, and pharmaceutical firms.

Recurring outbreaks remain a primary driver for market expansion, prompting regulatory approvals for multiple vaccines and treatments. For instance, Merck’s Ervebo vaccine received FDA approval in 2019 and has been deployed in targeted immunization campaigns. Therapeutics such as Regeneron’s Inmazeb and Mapp Biopharmaceutical’s ZMapp have also secured regulatory clearances, expanding available treatment options. Government and global health agency stockpiling initiatives have further stimulated demand.

Despite these advancements, the market faces challenges. The intermittent nature of outbreaks creates fluctuating demand, often leading to funding gaps during non-outbreak periods. Additionally, high production costs, clinical development expenses, and distribution complexities in remote regions pose operational hurdles.

Nevertheless, emerging opportunities are shaping future growth. Development of broad-spectrum antivirals and multi-strain vaccines represents a promising approach, potentially expanding applicability beyond Ebola to other hemorrhagic fevers. Advances in rapid diagnostic technologies are also expected to enhance outbreak management, contributing to overall market expansion.

For comprehensive insights, visit the Ebola Virus Market Insights @ https://www.delveinsight.com/report-store/ebola-virus-competitive-landscape

Snapshot of Pipeline Ebola Virus Candidates

• INO 4201: INOVIO Pharmaceuticals
• Ebola virus vaccine: Auro Vaccines
• Opaganib: RedHill Biopharma Ltd.
• RHB-107: RedHill Biopharma
• Pan–Ebola: Emergent BioSolutions
• ARN 75092: Arisan Therapeutics

Explore more about emerging therapies in the Ebola Virus Clinical Trials report

Scope of the Ebola Virus Pipeline Report

• Geographical Coverage: Global
• Key Companies Covered: Auro Vaccines, INOVIO Pharmaceuticals, RedHill Biopharma Ltd., Emergent BioSolutions, Arisan Therapeutics, TFF Pharmaceuticals, China Immunotech, and others
• Key Pipeline Therapies: Ebola virus vaccine, INO 4201, Opaganib, RHB-107, Pan–Ebola, ARN 75092, Viral vaccine research programs, EBV TCR T cell therapy, and others

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services